

[Open Peer Review on Qeios](#)

Anagrelide

National Cancer Institute

Source

National Cancer Institute. *Anagrelide*. NCI Thesaurus. Code C28825.

A synthetic quinazoline derivative, Anagrelide reduces platelet production through a decrease in megakaryocyte maturation. Anagrelide inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. At therapeutic doses, it does not influence white cell counts or coagulation parameters. Anagrelide is used for treatment of essential thrombocythemia to reduce elevated platelet counts and the risk of thrombosis. (NCI04)